# Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

> **NCT02430194** · PHASE2 · COMPLETED · sponsor: **Eiger BioPharmaceuticals** · enrollment: 55 (actual)

## Conditions studied

- Chronic Hepatitis D Infection

## Interventions

- **DRUG:** lonafarnib
- **DRUG:** ritonavir
- **DRUG:** Pegylated interferon-alfa-2a

## Key facts

- **NCT ID:** NCT02430194
- **Lead sponsor:** Eiger BioPharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-04-18
- **Final completion:** 2017-06-15
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02430194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02430194, "Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02430194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*